Source comparison
Melanotan-1 Side Effects: Dosing Comparison
Melanotan-1 side effects vary significantly with dosing schedule, administration route, and cumulative exposure. The following comparison synthesizes data from published clinical trials and research protocols to illustrate how protocol design influences advers
This comparison does not assign a generated winner or score.
- Melanotan-1 side effects vary significantly with dosing schedule, administration route, and cumulative exposure. The following comparison synthesizes data from published clinical trials and research protocols to illustrate how protocol design influences adverse event frequency.
- 1mg daily subcutaneous (cumulative 7mg/week)
- 20–25%
- 8–12%
- 10–15% at 1mg/mL concentration
- 6–10% after 4 weeks
- Lowest adverse event profile. Allows receptor downregulation between doses and maintains steady melanogenesis without peak plasma spikes
- 2mg every other day subcutaneous (cumulative 7mg/week)
- 25–30%
- 10–14%
- 12–18%
- 8–12% after 4 weeks
- Moderate profile. Slightly higher peak plasma levels increase nausea and cardiovascular effects, but alternate-day dosing permits partial receptor recovery
- 5mg twice weekly subcutaneous (cumulative 10mg/week)
- 35–42%
- 15–20%
- 20–28%
- 12–18% after 4 weeks
- Higher adverse event rates due to peak plasma concentration surges. Nausea and blood pressure effects correlate with dose magnitude rather than cumulative exposure
- 10–16mg single dose (clinical trial dosing for EPP)
- 40–50%
- 18–25%
- 25–35%
- 15–22% after 6 weeks
- Highest adverse event frequency. Used in therapeutic contexts where benefit-risk ratio favors maximal melanogenesis despite side effects; not recommended for cosmetic or metabolic research
- This table demonstrates that adverse event frequency scales more strongly with peak dose magnitude than with cumulative weekly exposure. Daily low-dose protocols produce equivalent melanin synthesis with 30–40% lower adverse event rates compared to twice-weekly higher-dose regimens.